Plasmid DNA, also known as recombinant DNA, is a small, circular, extra-chromosomal, double-stranded DNA (dsDNA) molecule that can replicate independently of the chromosomal DNA within a cell. It is used to introduce genetic material into host cells as it can self-replicate to produce multiple copies of the gene within the host genome or survive autonomously as non-integrating DNA. Key functions of plasmid DNA involve DNA cloning, exchanging genes between organisms, generating proteins of pharmacological relevance like insulin or growth factors, developing genetically modified organisms and engineering DNA and RNA vaccines. Rapidly expanding gene therapy and cell therapy markets have boosted the demand for plasmid DNA significantly.
The Global Plasmid DNA Manufacturing Market is estimated to be valued at US$ 1038.19 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Plasmid DNA Manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing.
The rising demand for gene therapies and cell therapies is driving the Plasmid DNA Manufacturing Market Demand Gene therapy development is now moving significantly from clinical trials to commercialization phase. Further, increasing need for DNA vaccines to combat COVID-19 pandemic has accelerated plasmid DNA demand.
Technological advancements like use of high-yield fermentation processes, use of chemically defined and animal component free media, automated plasmid DNA purification using anion-exchange chromatography are resulting in enhanced plasmid DNA yields, purity and consistency. This is enabling plasmid DNA manufacturers to efficiently meet escalating commercial demands.
Market Trends
Custom production using plasmids containing customer-specific genes is a major trend in the market. This is allowing pharmaceutical companies to outsource plasmid DNA production as required for their clinical trials and commercial requirements.
Another key trend is the shift towards serum-free and animal component free manufacturing process of plasmid DNA to meet regulatory expectations of leading global health authorities. This is enabling manufacturers to produce highly pure and safe plasmid DNA therapeutics.
Market Opportunities
One of the key opportunities in the market is the increasing need for plasmid DNA to enable rapid development of novel DNA and RNA vaccines for future pandemics. This provides scope for plasmid DNA manufacturers to collaborate with vaccine developers.
Another major opportunity lies in the growing demand for plasmid DNA therapeutics especially for cancer gene therapy. Successful approvals and subsequent commercialization of CAR-T cell therapies have stimulated plasmid DNA R&D for diverse oncology applications presenting significant growth potential.
Impact of COVID-19 on Plasmid DNA Manufacturing Market
The COVID-19 pandemic has significantly impacted the growth of the plasmid DNA manufacturing market. During the initial phases of the pandemic in 2020, many countries imposed stringent lockdowns and travel restrictions. This led to disruptions across the global pharmaceutical and biotechnology supply chains. Plasmid DNA manufacturing facilities also faced difficulties in procuring raw materials, conducting laboratory testing and shipping finished products. As a result, plasmid production capacity was reduced and many ongoing clinical trials involving gene and cell therapies faced delays.
However, as COVID-19 accelerated research focus on developing vaccines and therapeutics, demand for plasmids increased significantly post-2020. Major pharmaceutical companies rapidly scaled up their plasmid DNA production capabilities to support vaccine development programs. Contract development and manufacturing organizations also expanded their manufacturing footprints. The pandemic underscored the critical role of plasmid DNA in biopharmaceutical manufacturing. Researchers also leveraged plasmid vectors to develop potential therapies targeting SARS-CoV-2. Overall, while COVID-19 initially slowed market growth in the short term, it has driven greater awareness and investment in plasmid DNA production over the long term. Looking ahead, continued R&D in gene therapies and vaccines will support market expansion, though supply chain risks remain a key challenge.
Geographical Regions with Highest Plasmid DNA Manufacturing Market Value
North America currently accounts for the largest share of the global plasmid DNA manufacturing market in terms of value. Majority of large pharmaceutical companies and CDMOs with advanced plasmid production capabilities are headquartered in the US and Canada. Additionally, higher research spending on gene and cell therapies from both public and private organizations has fueled plasmid demand. Asia Pacific is expected to be the fastest growing regional market owing to improving biomanufacturing infrastructure in countries like China, South Korea and Singapore. Rising engagement of Asian CDMOs in contract development and manufacturing is also supporting the regional plasmid DNA market.
Fastest Growing Geographical Region for Plasmid DNA Manufacturing Market
Asia Pacific is poised to be the fastest growing region for the plasmid DNA manufacturing market during the forecast period from 2024 to 2031. Countries such as China, Japan, South Korea and Singapore offer a highly attractive combination of large target patient pools, lower costs and a growing technical skill-base. Domestic and multinational pharmaceutical firms are establishing ample gene therapy manufacturing capacities across Asia to cater to the local and global demand. Abundant investments from governments as well as private organizations in the biotech sector have created a fertile environment for plasmid DNA market growth. As the region solidifies its position as a global biomanufacturing hub, its share in the plasmid DNA market is expected to rise rapidly over the coming years.
Get More Insights On, Plasmid DNA Manufacturing Market
Comments
0 comment